Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)

被引：29

作者：

Lee, Sang Hoon ^{[1
]}

机构：

[1] PharmAbcine, Taejon 305811, South Korea

来源：

ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 08期

关键词：

TUMOR ANGIOGENESIS; THERAPY; DISEASE;

D O I：

10.1007/s12272-011-0821-9

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).

引用

页码：1223 / 1226

页数：4

共 50 条

[41] Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor Ⅱ
Rong LI
ActaPharmacologicaSinica, 2004, (10) : 52 - 58
[42] Meloxicam Temporally Inhibits the Expression of Vascular Endothelial Growth Factor Receptor (VEGFR)-1 and VEGFR-2 During Alveolar Bone Repair in Rats
Nunes Arantes, Ricardo Vinicius
Cestari, Tania Mary
Viscelli, Bruno Alvares
Dionisio, Thiago Jose
Garlet, Gustavo Pompermaier
Santos, Carlos Ferreira
de Assis, Gerson Francisco
Taga, Rumio
JOURNAL OF PERIODONTOLOGY, 2015, 86 (01) : 162 - 172
[43] Vascular Endothelial Growth Factor and Its High-Affinity Receptor (VEGFR-2) Are Highly Expressed in the Human Forebrain and Cerebellum During Development
Sentilhes, Loic
Michel, Christine
Lecourtois, Magalie
Catteau, Julie
Bourgeois, Philippe
Laudenbach, Vincent
Marret, Stephane
Laquerriere, Annie
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2010, 69 (02): : 111 - 128
[44] Short Report: Elevated Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Vascular Endothelial Growth Factor Receptor (VEGFR)-2 in Human Malaria
Furuta, Takahisa
Kimura, Mikio
Watanabe, Naohiro
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 82 (01): : 136 - 139
[45] A fully human anti-vascular endothelilal growth factor receptor 2 (VEGFR2) IGG1 monoclonal antibody (MAB) therapy in patients with advanced cancer
Youssoufian, H.
Rowinsky, E. K.
Fox, F.
Hicklin, D.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (04) : 383 - 383
[46] Vascular endothelial growth factor (VEGF) isoform mediated tumour response to combination treatment with a blocking antibody to VEGFR-2 and radiotherapy
Mukherjee, D.
Lunt, S. J.
Fisher, M.
English, W.
Kanthou, C.
Tozer, G.
EUROPEAN JOURNAL OF CANCER, 2016, 61 : S146 - S146
[47] Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTACAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
Lee, Weon Sup
Shim, Sang Ryeol
Lee, Seon Young
Yoo, Jin San
Cho, Sung Kweon
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 495 - 504
[48] Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2
Zhang, HF
Li, YW
Li, HL
Bassi, R
Jimenez, X
Witte, L
Bohlen, P
Hicklin, DJ
Zhu, ZP
LEUKEMIA & LYMPHOMA, 2004, 45 (09) : 1887 - 1897
[49] Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening
Chelliah, Selvam
Mock, Charlotta D.
Mathew, Omana P.
Ranganna, Kasturi
FASEB JOURNAL, 2018, 32 (01):
[50] Expression of Vascular Endothelial Growth Factor Receptor 1(VEGFR-1), but not VEGFR-2 in Activated T Lymphocytes and Its Function in Response to VEGF
Shin, Jin Young
Kim, Jung Sik
Kim, Bongi
Yun, Il Hee
Park, Chung Gyo
JOURNAL OF IMMUNOLOGY, 2007, 178

← 1 2 3 4 5 →